Innovation Pharmaceuticals Inc (IPIX)

[Lemoncat]

I think there are plenty of BPs that would take on the development of Kevetrin from here.

$50 million + trial costs + milestones + 5-10% royalties is probably achievable right now for Kevetrin. Those are relatively small upfronts to lock in a majority stake on a safe, potential p53 modulator. BPs routinely shell out more than that for me-too PD-1 and other preclinical IO targets. People focus on the tiny phase 2a too much...in the bleeding edge cancer treatment arena, BPs pay up for far less than what Kevetrin has demonstrated.

I think oral formulation with another 10-20 patient phase 2a to confirm both the formulation and confirm the previous pre-clinical and clinical results would greatly increase that offer with a minimal cost to IPIX (assuming we get a decent upfront on a B deal).